#USA #New York #Robbins Geller #class action lawsuit #MoonLake Immunotherapeutics

MoonLake Immunotherapeutics and Investor Action

In a significant development for shareholders, legal firm Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit involving MoonLake Immunotherapeutics, a company specializing in therapeutic solutions for inflammatory diseases. The case, titled Peters v. MoonLake Immunotherapeutics, is currently underway in the Southern District of New York. It specifically addresses serious allegations against both the company and its executives, suggesting violations of the Securities Exchange Act of 1934.

The Core of the Allegations

MoonLake is primarily focused on developing treatments for conditions such as hidradenitis suppurativa (HS) through its main drug candidate, sonelokimab (SLK). The lawsuit emphasizes that MoonLake claimed SLK would match or outpace the effectiveness of BIMZELX, an FDA-approved monoclonal antibody treatment for the same medical conditions. However, the class action points to misleading statements made by MoonLake that concealed critical details about SLK's safety and efficacy profile.

One of the central allegations is that SLK shares similar molecular targets with BIMZELX, namely the inflammatory cytokines IL-17A and IL-17F, which the complaint suggests undermines MoonLake's claims of SLK offering novel clinical benefits. These claims were severely impacted when it was announced on September 28, 2025, that SLK failed to demonstrate competitive efficacy in clinical trials against its competitor BIMZELX, leading to a drastic plummet of almost 90% in MoonLake's stock price.

The Lead Plaintiff Opportunity

Under the Private Securities Litigation Reform Act of 1995, any investor who purchased MoonLake common stock during this tumultuous period is otherwise eligible to step up as the lead plaintiff in the class action. The lead plaintiff is typically the party who has the highest financial stake and is deemed representative of the affected shareholders. Crucially, being declared the lead plaintiff allows one to select their preferred legal firm to manage the case. However, investors should note that participation as lead plaintiff does not impact their potential to recover financial losses should the case yield a favorable outcome.

Potential lead plaintiffs must submit their motions to the court by December 15, 2025, to be considered.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is a well-regarded law firm recognized for its commitment to representing investors in cases of securities fraud and litigation associated with shareholder disputes. The firm has earned accolades for securing over $2.5 billion for investors involved in securities class actions in just 2024, outperforming its closest competitors significantly. With a robust team of attorneys across various offices, Robbins Geller boasts experience in handling some of the largest recoveries in history within this sector.

For those who wish to learn more, further information regarding this class action lawsuit against MoonLake Immunotherapeutics is available through Robbins Geller’s official website. Interested investors are encouraged to reach out to the attorneys involved for additional clarity regarding their rights and available options in response to potential financial losses incurred through their investment in MoonLake Immunotherapeutics.

In summary, this looming class action lawsuit presents an essential avenue for affected investors seeking accountability and financial restitution following the recent market shocks surrounding MoonLake Immunotherapeutics. Legal professionals and affected parties alike are keeping a close eye on proceedings as they evolve in the coming weeks.